Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quiescent OXPHOS-High Triple-Negative Breast Cancer Cells That Persist After Chemotherapy Depend on BCL-XL for Survival.

Cells·2025

Same author

Quiescent OXPHOS-high triple-negative breast cancer cells that persist after chemotherapy depend on BCL-XL for survival.

bioRxiv : the preprint server for biology·2025

Same author

Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias.

Nature cancer·2023

Same author

Genome-scale screens identify factors regulating tumor cell responses to natural killer cells.

Nature genetics·2021

Same author

Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence.

Cancer discovery·2021

Same author

An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence.

Cancer cell·2021

Same journal

Discovery and optimization of a pH-responsive ultra-long-acting VHH-based growth hormone mimetic.

mAbs·2026

Same journal

Efficient inference of non-polyreactive antibody variants dependent on local fine-tuning.

mAbs·2026

Same journal

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026

Same journal

Development of single-chain C1q affinity chromatography-mass spectrometry for the glycoform-resolved characterization of low-affinity immunoglobulin G interactions.

mAbs·2026

Same journal

Biparatopic targeting of IL-23 enables dual-epitope engagement and enhanced neutralization potency.

mAbs·2026

Same journal

Comparison of knockdown approaches for the generation of stable cell populations expressing afucosylated antibodies.

mAbs·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Canakinumab.

Eugen Dhimolea¹

¹Tufts University School of Medicine, Boston, MA, USA. eugen.dhimolea@tufts.edu

|January 13, 2010

Summary

This summary is machine-generated.

Canakinumab is a targeted therapy that neutralizes IL-1beta to reduce inflammation in autoimmune diseases. It is approved for rare inflammatory syndromes and shows promise for other conditions, with good tolerability.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Related Experiment Videos

Last Updated: Jun 17, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Dioscin Mediated IgA Nephropathy Alleviation by Inhibiting B Cell Activation In Vivo and Decreasing Galactose-Deficient IgA1 Production In Vitro

Published on: October 13, 2023

Area of Science:

Immunology
Pharmacology
Rheumatology

Background:

Canakinumab is a human monoclonal antibody targeting interleukin-1 beta (IL-1beta).
IL-1beta signaling plays a key role in inflammatory disorders of autoimmune origin.
Autoimmune diseases encompass a range of conditions characterized by inappropriate immune system activity.

Purpose of the Study:

To review the mechanism of action, therapeutic applications, and clinical profile of canakinumab.
To highlight its efficacy and safety in approved indications and ongoing investigations.
To compare canakinumab with existing treatment options for inflammatory diseases.

Main Methods:

Review of preclinical and clinical trial data.
Analysis of drug approval information from regulatory agencies.
Pharmacological assessment of IL-1beta inhibition.

Main Results:

Canakinumab effectively neutralizes IL-1beta, suppressing inflammation.
Approved for familial cold auto-inflammatory syndrome and Muckle-Wells syndrome.
Demonstrates good tolerability with no serious adverse effects reported in trials.
Potential applications being explored in rheumatoid arthritis, juvenile idiopathic arthritis, COPD, diabetes, and ocular diseases.

Conclusions:

Canakinumab offers a targeted approach to managing IL-1beta-mediated inflammation.
Its established safety profile and convenient dosing present advantages in treating specific autoimmune and inflammatory conditions.
Further research may expand its therapeutic utility across a broader spectrum of diseases.